Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma

Autor: Willemijn Theelen, O Krijgsman, K Monkhorst, T Kuilman, DDGC Peters, S Cornelissen, M Ligtenberg, SM Willems, JLG Blaauwgeers, CJM van Noesel, DS Peeper, MM van den Heuvel, K Schulze

The authors have removed this preprint from Research Square.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ac60376d516046774498019db5601cb
https://doi.org/10.21203/rs.3.rs-26299/v1

Long-term risk and characteristics of cerebrovascular events after upper body radiotherapy among childhood cancer survivors in the DCCSS-LATER cohort.

Autor: Verbruggen LC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Kok JL; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Kremer LCM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Emma Children's Hospital, University of Amsterdam, Amsterdam, The Netherlands.; University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands., Janssens GO; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Nederkoorn PJ; Department of Neurology, Amsterdam UMC, AMC, University of Amsterdam, Amsterdam, The Netherlands., Penson A; Radboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Versluijs AB; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology and Hematology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands., de Vries ACH; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology/Hematology, Sophia Children's Hospital/Erasmus Medical Center, Rotterdam, The Netherlands., Reedijk AMJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Bresters D; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Hoving EW; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van Dulmen-den Broeder E; Department of Pediatric Oncology/Hematology, Amsterdam UMC/VUmc, Amsterdam, The Netherlands., Loonen JJ; Radboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., de Bont J; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Wilbers J; Radboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Louwerens M; Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands., van der Heiden-van der Loo M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology/Hematology, Sophia Children's Hospital/Erasmus Medical Center, Rotterdam, The Netherlands., Pluijm SMF; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Neggers SJCMM; Department of Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands., Tissing WJE; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology/Hematology, University of Groningen/Beatrix Children's Hospital/University Medical Center Groningen, Groningen, The Netherlands., Roos YBWEM; Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Ronckers CM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Division of Childhood Cancer Epidemiology (EpiKiK), Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany., Teepen JC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van der Pal HJH; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Dec 16. Date of Electronic Publication: 2024 Dec 16.

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.

Autor: Verkerk K; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Wel TJWT; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Zeverijn LJ; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Geurts BS; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Spiekman IAC; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., de Wit GF; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands., Smit EF; Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands., Hoeben A; Division of Medical Oncology, Department of Internal Medicine, GROW School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Hendriks LEL; Department of Pulmonology, GROW - School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., van den Heuvel MM; Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands., Piet B; Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands., Herder GJM; Department of Pulmonology, Meander Medical Center, Amersfoort, the Netherlands., Hashemi SMS; Department of Pulmonary Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Center for Personalized Cancer Treatment, the Netherlands., de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Dec 02; Vol. 30 (23), pp. 5323-5332.

Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review.

Autor: Sprokkerieft J; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: j.sprokkerieft@prinsesmaximacentrum.nl., van der Beek JN; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Spreafico F; Pediatric Oncology Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Selle B; Hopp Children's Cancer Center Heidelberg (KiTZ) & Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany., Chowdhury T; Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom., Graf N; Department of Pediatric Oncology and Hematology, Saarland University, Homburg, Germany., Verschuur AC; Department of Pediatric Hematology-Oncology, Hôpital d'Enfants de la Timone, APHM, Marseille, France., Dandis R; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Bex A; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam 1066CX, the Netherlands; Division of Surgical and Interventional Science, The Royal Free London NHS Foundation Trust and UCL, London, UK., Geller JI; Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, USA., Tytgat GAM; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van den Heuvel-Eibrink MM; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Publikováno v: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2024 Dec; Vol. 204, pp. 104523. Date of Electronic Publication: 2024 Sep 24.

Prevalence and determinants of dyslipidemia in 2,338 Dutch childhood cancer survivors: a DCCS-LATER 2 Study.

Autor: Bolier M; Dept. of Internal Medicine, section Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Pluimakers VG; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., de Winter DTC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Fiocco M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Dept. of Biomedical Data Science, section Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands.; Mathematical Institute Leiden University, Leiden, The Netherlands., van den Berg SAA; Dept. of Internal Medicine, section Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.; Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands., Bresters D; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van Dulmen-den Broeder E; Pediatric Oncology, Cancer Center Amsterdam, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., van der Heiden-van der Loo M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Höfer I; Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands., Janssens GO; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Dept. of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Kremer LCM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Dept. of Pediatric Oncology, Emma Children's Hospital/Amsterdam UMC, Amsterdam, The Netherlands., Loonen JJ; Dept. of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Louwerens M; Dept. of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands., van der Pal HJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Pluijm SMF; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Tissing WJE; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Dept. of Pediatric Oncology/Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., van Santen HM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Dept. of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, Netherlands., de Vries ACH; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pediatric Oncology, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, Netherlands., van der Lely AJ; Dept. of Internal Medicine, section Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands., van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands., Neggers SJCMM; Dept. of Internal Medicine, section Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Publikováno v: European journal of endocrinology [Eur J Endocrinol] 2024 Nov 20. Date of Electronic Publication: 2024 Nov 20.